Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (31)
NITAG documentation (1591)
Reports (55)
SAGE documentation (222)
Scientific publications (112)
Systematic reviews (SYSVAC) (2853)
Regions
Africa (274)
Americas (766)
Eastern Mediterranean (50)
Europe (705)
South-East Asia (81)
Western Pacific (199)
Diseases
Chikungunya (9)
Cholera (34)
COVID-19 (1513)
Cytomegalovirus (1)
Dengue (40)
Diphtheria (80)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (68)
Hepatitis A (64)
Hepatitis B (157)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (68)
HIV / AIDS (10)
Human papillomavirus (HPV) (493)
Influenza (581)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (28)
Measles (130)
Meningococcal disease (148)
Moraxella catarrhalis (1)
Mpox (55)
Mumps (46)
Pertussis (105)
Pneumococcal disease (277)
Poliomyelitis (86)
Q fever (1)
Rabies (29)
Rotavirus (117)
RSV (Respiratory syncytial virus) (48)
Rubella (64)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (60)
Tick-borne encephalitis (12)
Tuberculosis (77)
Typhoid (24)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4864 results found
2025
RSV immunisation programme: JCVI advice, 16 July 2025
2025
∙
JCVI
JCVI statement on COVID-19 vaccination in autumn 2026 and spring 2027
2025
∙
JCVI
JCVI statement on influenza vaccines for 2026 to 2027
2025
Recommendation on the introduction of a Hepatitis B vaccine birth dose in Lesotho
2025
∙
SAGE
Meeting of the Strategic Advisory Group of Experts on Immunization, March 2025: Conclusions and recommendations
2025
∙
WHO
WHO position paper on herpes zoster vaccines
2025
∙
WHO
WHO position paper on Respiratory Syncytial Virus (RSV)
2025
∙
Haute Autorité de Santé
H5N1 zoonotic influenza in France
2025
∙
Haute Autorité de Santé
Seasonal flu vaccination for people aged 65 and over in France. Role of the Efluelda and Fluad vaccines
2025
∙
Haute Autorité de Santé
Papillomavirus vaccination in France: expansion of the catch-up vaccination cohort in men and women up to the age of 26
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
